Wound Care Biologics Market – By Product Type, By Wound Type, By End Use – Global Forecast 2025 – 2034

Wound Care Biologics Market Size

The global wound care biologics market size was valued at USD 2.2 billion in 2024 and is expected to reach USD 3.6 billion in 2034, growing at a CAGR of 5.2% from 2025 to 2034. Wound care biologics are advanced bioengineered products aimed at assisting in curing non-healing wounds, by stimulating the body’s natural healing mechanisms. Such advanced treatments are designed to trigger the body’s innate healing capabilities, minimizing the chances of function and mobility loss, including amputation.
 

The developing and underdeveloped regions have been observing an increasing number of burn wounds. Thus, the demand of wound care biologics is further increasing. The lack of severe medical attention, inadequate facilities, and increased chances of infection prolong the healing of the wound with many complications especially in the underdeveloped regions. For instance, according to the World Health Organization (WHO), roughly 180,000 fatalities are caused due to burns each year with the majority of these coming from lower and medium-income countries.
 

Furthermore, every year, more than 6 million people face the problem of suffering from burns that are moderate to severe which results in increased hospital admissions. The recognition of biologic solutions using advanced wound care, is positively transforming patient outcomes alongside the difficulties of burn infection control and tissue regeneration.
 

Moreover, the global surge in the elderly demographic is shifting its focus towards the demand for wound care biologics due to geriatric population suffering from chronic wounds such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers. The United Nations (UN) estimates that the world population aged 65 years and above is expected to reach 1.6 billion by 2050, which is nearly double the 761 million from 2021. In addition, over 15% of the elderly population is estimated to be suffering from chronic wounds which increases the amount of time and money spent on the healthcare system. Wound care biologics aid in tissue repair for the increasing elderly population and reduce complications, thereby boosting the market growth.
 

 Wound Care Biologics Market Trends

• Rise in demand of regenerative wound care biologics, such as growth factors, skin substitutes, and extracellular matrix-based products, by healthcare providers is accelerating the market development. These products facilitate healing chronic wounds such as diabetic foot ulcers and pressure ulcers.
   
• Key players are expanding their biologics portfolio to provide more comprehensive and targeted healing products. For instance, Apligraf, a bi-layered skin substitute developed by Organogenesis, has a high healing rate in venous leg ulcers. Similarly, Smith & Nephew’s GrafixPL has also been improving healing in diabetic foot ulcers.
   
• Furthermore, ready-to-use biologic dressings and grafts are more preferable than tissue-based autologous therapies because of their ease-of-use and lesser time needed for preparation.
   
• Another advancing trend is the rise of home-based wound management, driven by telehealth adoption and portable biologic dressing solutions. The growth of the home healthcare market, which is expected to reach USD 555.6 billion by 2032, is further supporting this shift.
   
• In addition to this, another focus area for manufacturers is sustainable packaging solutions by using biodegradable materials and minimizing plastic waste. Companies are investing in eco-friendly alternatives, such as bio-based polymers, for wound biologics packaging.
   
• For instance, Molnlycke has implemented sustainable manufacturing processes for its wound care biologics, reducing carbon emissions by 20% and cutting plastic usage by 30% in packaging. Such innovative product launches are contributing to the progression of the market.
   

Wound Care Biologics Market Analysis

Based on product type, the market is segmented into skin substitutes and topical agents. The global market for wound care biologics was valued at USD 2.1 billion in 2023. The skin substitutes segment dominated the market with the largest revenue of USD 1.4 billion in 2024.
 

• Skin substitutes segment dominated the market as they provide structural support and promote tissue regeneration in chronic and acute wounds. These solutions can be derived from human, animal, or synthetic sources, and are designed to improve the wound healing.
   
• Increasing chronic wounds is a leading cause of this segment’s dominance. According to the International Diabetes Federation (IDF), it is estimated that 19 –34% of diabetic patients will develop a foot ulcer in their lifetime, with over 9.1 –26.1 million diabetic foot ulcer (DFU) cases annually worldwide.
   
• Moreover, skin substitutes help in reducing wound closure time, as well as they also minimize infection risks in various cases of diabetic foot ulcers, pressure ulcers and burn injuries, hence boosting segmental growth.
   

Based on wound type, the wound care biologics market is segmented into diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, burns and other wound types. The surgical wounds segment emerged as a dominant segment in the market, accounting for 27% of revenue share in 2024 and is expected to reach by USD 877.5 million in 2034.
 

• The segment is dominant due to an increase in the need for healthcare professionals to minimize surgical site infections (SSIs), enhance tissue regeneration, and expedite healing post-surgery.
   
• This demand is further fueled by the increasing elderly population and growing orthopedic, cardiovascular, and reconstructive procedures. According to the WHO, there are approximately 313 million surgical procedures carried out globally every year, many of which are accompanied by advanced wound care needs.
   
• Thus, the increased surgery burden is responsible for the high market share of this segment in the market.
   

Based on end use, the wound care biologics market is segmented into hospitals, ambulatory surgical centers, and other end users. Hospitals segment accounted for the largest revenue share of 43.8% in 2024.
 

• The primary users of wound care biologics are the hospitals which are important in the management of acute and chronic wounds such as diabetic foot ulcers, pressure ulcers, burns, and post-surgical wounds.
   
• The increased utilization of biologic wound care products by hospitals is because of the adoption of advanced skin substitutes, growth factor therapies, and collagen-based dressings, which all strive to enhance the healing outcomes and decrease infection rates.
   
• Further, the market growth for biologics is boosted by specialized outpatient and wound care settings that incorporate biologics into their treatment protocols for complex wounds.
   
• Hospitals are expanding their regenerative therapy services by adding placental tissue allografts and autologous cell-based therapies due to an increase in diabetes and vascular diseases for higher wound closure rates, thereby boosting the adoption of wound care biologics and further driving the segmental growth.
   

The U.S. wound care biologics market revenue has increased considerably from USD 730.8 million in 2023 and is expected to grow significantly, reaching USD 1.2 billion by 2034.
 

• The chronic wounds in the U.S. are impacting quality of life of the residents. For instance, according to the National Institute of Health (NIH), in 2022, chronic wounds impacted the quality of life of approximately 2.5% of the total population across the U.S.
   
• In addition to this, the U.S. has an increasing diabetic population, which is expected to contribute to the chronic wounds surge. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), as of 2021, over 38.4 million individuals in the country had diabetes. Moreover, it is estimated that with up to 34% of people with type 1 or type 2 diabetes have risk of developing diabetic foot ulcers.
   

Europe: The UK wound care biologics market is projected to experience steady growth between 2025 and 2034.
 

• The number of chronic wound cases are increasing along with the growing elderly population in the UK.
   
• Moreover, owing to the progress of regenerative medicine, the market in the UK is steadily growing. The National Health Service (NHS) figures suggest that approximately 3.8 million individuals in the UK suffer from wounds every year out of which a substantial number have chronic wounds.
   
• Further, the aging population in the UK is another fundamental reason for the expansion of the market since people aged 65 and above are likely to suffer from chronic wounds.
   

Asia Pacific: Japan wound care biologics market is poised to witness lucrative growth between 2025 – 2034.
 

• Japan observes a massive aging society; according to Statista, as of November 2023, approximately 36.35 million people in Japan were estimated to be over 65 years of age.
   
• Therefore, it is expected that an aging society will require a strong wound management system in the near future and hence the market of wound care biologics in the country is expected to rise.
   

Middle East and Africa: The wound care biologics market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is also experiencing an aging population. For instance, the number of people aged 60 and above are expected to rise five times from 2 million (5.9% of the total population) in 2020, reaching 10.5 million by 2050.
   
• Such high trends in the aging population are expected to increase the demand for wound care biologics in coming years.
   

Wound Care Biologics Market Share

The top five competitors in the wound care biologics sector are Smith & Nephew, Organogenesis Holdings Incorporation, Convatec Group, Integra LifeSciences, and MiMedx Group. These corporations use new clinical procedures and are involved in product innovations. They are also strategically partnering with the organizations such as research institutions and government agencies. In addition, these companies are also expanding their capacities to produce advanced biologics to be ahead in the competition.
 

For instance, in June 2022, Smith & Nephew declared they are going to invest over USD 100 million into a new research and development and manufacturing plant for their advanced wound management division located in Hull, UK. Moreover, emerging players such as Kerecis, Solsys Medical, and Skye Biologics are leveraging novel technologies such as fish-skin grafts, amniotic tissue-based products, and advanced regenerative therapies to enhance wound healing outcomes.
 

 Wound Care Biologics Market Companies

Some of the eminent market participants operating in the wound care biologics industry include:

• 3M
• Amnio Technology
• Avita Medical
• Convatec
• Derma Sciences
• Integra Life Sciences
• Kerecis
• Mimedx Group
• Molnlycke Health Care
• Organogenesis
• Osiris Therapeutics
• Skye Biologics
• Smith & Nephew
• Solsys Medical
• Vericel Corporation
• Wright Medical
   
• Smith & Nephew is a key player in this market, with strong presence globally, which helps in maintaining a strong distribution network all over the world. The company has operations in over 100 countries and a strong focus on clinical research.
   
• Organogenesis Holdings Inc. has a diversified offering of skin substitutes which include extensive portfolio. For instance, Apligraf and Dermagraft products, are used extensively in the treatment of diabetic foot ulcers and venous leg ulcers, strengthening the company’s position in the biologics market.
   
• Vericel Corporation is a strong player in the wound care sector. For instance, Epicel is an FDA-approved permanent skin replacement for patients with deep dermal or full-thickness burns covering over 30% of total body surface area. Additionally, MACI (Matrix-Induced Autologous Chondrocyte Implantation), is another FDA-approved product, used for cartilage repair, demonstrating the company’s expertise in regenerative medicine and advanced biologics.
   

Wound Care Biologics Industry News:

• In March 2022, Convatec Group Plc acquired Triad Life Sciences Inc., a U.S. based medical device company which was a manufacturer of biologically derived products for surgical wounds, chronic wounds, and burns. This acquisition marked Convatec’s entry into the wound care biologics market, enhancing its portfolio to address unmet clinical needs.
   
• In September 2022, MiMedx Group, Inc. introduced AMNIOEFFECT, a tri-layer PURION processed human tissue allograft designed for surgical wound management. This innovation enhanced the company’s surgical recovery portfolio and strengthened its position in this market owing to the introduction of this new product.
   
• In February 2020, Integra LifeSciences launched the Amnio Excel Plus Placental Allograft Membrane, which was designed to support repair of soft tissue as its latest advancement in biological wound healing therapy. With this launch, Integra expanded its wound care biologics portfolio, supporting its commitment to providing innovative solutions for complex wound management.
   

The wound care biologics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Skin substitutes
  • Biological
    • Allograft
    • Xenograft
    • Other biological skin substitutes
  • Synthetic
• Topical agents

Market, By Wound Type

• Diabetic foot ulcers
• Venous leg ulcers
• Pressure ulcers
• Surgical wounds
• Burns
• Other wound types  

Market, By End Use

• Hospitals 
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE